Compare Biogen Inc (BIIB) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs DuPont de Nemours Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while DuPont de Nemours Inc trades at $144.26 (market cap $19.51B). The key difference: Biogen Inc is the larger of the two by market cap, and DuPont de Nemours Inc pays a 1.66% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DD | |
|---|---|---|
Market Cap | $30.13B | $19.51B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $154.59 |
52-Week Low | $128.93 | $90.24 |
Enterprise Value | $37.20B | $20.90B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
DuPont (DD) trades at $144.65, up 2.18% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $232.80. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and industrial water demand, leading to a raised full-year 2026 outlook. The company announced strategic wins, including a membrane bioreactor system in Australia and an R&D 100 Award, highlighting innovation strength.
The stock presents growth potential from operational improvements and end-market recovery, but risks include a high P/E ratio of 62.01, net income margin of only 0.79%, and legal settlements over PFAS chemicals. Investor sentiment is positive due to earnings beats and raised guidance, though valuation concerns and liability exposures warrant caution for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
